Running a global Phase II or Phase III clinical trial means operating in regulatory environments across Europe, Asia-Pacific, Latin America, the Middle East, and North America — simultaneously. Each country has its own regulatory authority, its own submission format, its own review timeline, and its own import/export permit process for investigational medicinal products (IMPs). Coordinating this landscape is not a function that scales on spreadsheets and email — it requires dedicated administrative infrastructure.
According to Transcelerate Biopharma's benchmarking data, the average global Phase III trial is conducted in 15–30 countries and involves 100–400 sites. The administrative activity generated by country regulatory submissions, IMP logistics, site payment processing, and CTA execution for a trial of that scale is measured in thousands of document and communication events. Attempting to manage that volume without dedicated administrative support produces the delays and compliance gaps that are endemic in global clinical programs.
Country Regulatory Submission Tracking
Each country in a global trial requires a country-level regulatory authority submission — a Clinical Trial Authorization (CTA) in the EU, a Clinical Trial Application through the relevant national authority in each participating country, or an equivalent submission depending on jurisdiction. The timeline for approval varies from 30 days to 6+ months, and the readiness date for each country must be tracked relative to the global enrollment plan.
A global clinical operations VA maintains a country regulatory tracker covering submission date, expected approval date, actual approval date, and any hold or information request status for each participating country. This tracker feeds directly into the enrollment timeline, allowing the operations lead to identify bottlenecks before they cause overall program delays. The VA also tracks country-specific protocol translation and labeling requirements that must be completed before approval can be sought.
Import/Export Permit Coordination for Investigational Product
Shipping investigational product across international borders requires import and export permits, temperature-qualified logistics, and customs documentation. Import permit timelines vary dramatically by country — some require permits renewed for each shipment, others provide blanket authorization for the trial duration. Missing or expired permits halt IMP shipments and trigger enrollment stops at affected sites.
A VA maintains a per-country import permit tracker, monitors expiry dates, initiates renewal requests to the sponsor's logistics team or third-party import agent ahead of permit expiry, tracks shipment confirmations, and files shipping documentation in the TMF. This logistics coordination function is one of the most operationally consequential administrative tasks in global operations — and one of the most consistently under-resourced.
Site Payments Reconciliation
Clinical trial site payments — covering per-patient enrollment fees, visit fees, startup costs, and pass-through expenses — are processed on complex schedules tied to patient enrollment milestones and visit completion. Multi-country programs with 200+ sites generate monthly payment processing volumes that require systematic tracking to prevent disputes, overpayments, or delayed payments that damage site relationships.
A global clinical operations VA maintains the site payment tracker, cross-references payment schedules against enrollment and visit completion data, flags discrepancies to the finance team, and ensures payment records align with executed site budget agreements. For operations leads managing sponsor relationships, this visibility into site payment status is also a relationship management tool — sites that are paid accurately and on time are more likely to prioritize enrollment.
CTA Execution Tracking
Clinical Trial Agreements govern the legal and financial relationship between the sponsor and each participating site. In multi-country trials, CTAs must be negotiated, executed, and archived for each site — a process that can take months and that is notoriously difficult to track across jurisdictions, legal teams, and institutional review processes.
A VA maintains a CTA execution tracker covering negotiation status, outstanding redline versions, legal team assignments, expected execution date, and final executed agreement archiving. The VA coordinates version exchanges between sponsor legal and site contracting offices, tracks response timelines, and escalates stalled negotiations that are blocking site activation.
Global operations teams ready to bring order to their multi-country administrative landscape can learn more at Stealth Agents.
Sources
- Transcelerate Biopharma, Global Clinical Trial Benchmarking Report 2024
- Center for Information and Study on Clinical Research Participation (CISCRP), Global Trial Operations Survey 2024
- FDA, 21 CFR 312 — Investigational New Drug Application
- EMA, Clinical Trial Regulation (EU) No 536/2014